Estrella Immunopharma, Inc. (ESLAW)
USD 0.05
(-45.12%)
USD 0.05
(-45.12%)
| Breakdown | 2024 | 2022 | 2022 | 2021 |
|---|---|---|---|---|
| Operating Cash Flow | -16.06 Million | -1.04 Million | -1.44 Million | -670.82 Thousand |
| Net Income | -7.31 Million | -996.1 Thousand | -1.68 Million | -733.69 Thousand |
| Depreciation & Amortization | - | - | - | - |
| Deferred income taxes | - | 29.47 Thousand | - | - |
| Stock-based compensation | 1.19 Million | - | 129.96 Thousand | 62.87 Thousand |
| Change in working capital | -9.95 Million | 576.85 Thousand | 113.35 Thousand | - |
| Other non-cash items | 1.19 Million | -654.07 Thousand | -1428.00 | - |
| Investing Cash Flow | 4.96 Million | 36.17 Million | -45.18 Million | - |
| Investments in PPE | -4.00 | - | - | - |
| Acquisitions | - | - | - | - |
| Investment purchases | - | - | -45.18 Million | - |
| Sales/Maturities of investments | - | 36.17 Million | - | - |
| Other Investing Activities | 4.96 Million | - | - | - |
| Financing Cash Flow | 12.79 Million | -35.56 Million | 5.53 Million | 670.82 Thousand |
| Debt repayment | - | -498.6 Thousand | - | - |
| Dividends payments | - | - | - | - |
| Common Stock Repurchased | -354.44 Thousand | -36.11 Million | -25 Thousand | - |
| Common Stock Issuance | 9.02 Million | - | 46.89 Million | - |
| Other Financing Activities | 4.12 Million | 50 Thousand | -41.33 Million | 670.82 Thousand |
| Accounts receivables | - | - | - | - |
| Accounts payables | -9.33 Million | - | - | - |
| Inventory | - | - | - | - |
| Other working capital | -618.09 Thousand | 576.85 Thousand | 113.35 Thousand | - |
| Cash at beginning of period | 2.47 Million | 478.86 Thousand | - | - |
| Cash at end of period | 4.16 Million | 40.8 Thousand | 4.08 Million | - |
| Capital Expenditure | -4.00 | - | - | - |
| Effect of forex changes on cash | - | 1.00 | 45.18 Million | - |
| Net cash flow / Change in cash | 1.68 Million | -438.06 Thousand | 4.08 Million | - |
| Free Cash Flow | -16.06 Million | -1.04 Million | -1.44 Million | -670.82 Thousand |
| Breakdown | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -3.95 Million | -469.53 Thousand | -1.02 Million | -1.87 Million | -76 Thousand | -63.32 Thousand |
| Depreciation & Amortization | - | - | - | - | - | 5488.00 |
| Deferred income taxes | - | - | - | - | 598.00 | -21.7 Thousand |
| Stock-based compensation | - | - | - | 1.19 Million | - | 102.39 Thousand |
| Change in working capital | 3.65 Million | -3.76 Million | -10.24 Million | 400.65 Thousand | -22.95 Thousand | -84.9 Thousand |
| Other non-cash items | -9.95 Million | 77.07 Thousand | 9.26 Million | 1.19 Million | -114.31 Thousand | -105.79 Thousand |
| Investing Cash Flow | - | - | 5.07 Million | -112.29 Thousand | 21.43 Thousand | 77.77 Thousand |
| Investments in PPE | 3.00 | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | -136.53 Thousand | -136.53 Thousand |
| Sales/Maturities of investments | - | - | - | - | 157.96 Thousand | 214.3 Thousand |
| Other Investing Activities | - | - | 5.07 Million | -112.29 Thousand | - | - |
| Financing Cash Flow | -270.34 Thousand | -84.09 Thousand | -6.89 Million | 20.04 Million | 196.53 Thousand | 186.53 Thousand |
| Debt repayment | -10 Million | - | -300 Thousand | -10.3 Million | -196.53 Thousand | -186.53 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -270.34 Thousand | -84.09 Thousand | -5.07 Million | - | - | - |
| Common Stock Issuance | 10 Million | - | - | 10 Million | - | - |
| Other Financing Activities | 6.15 Million | - | -1.52 Million | 20.34 Million | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | -77.07 Thousand | -9.26 Million | 4498.00 | - | 2.55 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | 3.65 Million | -3.68 Million | -985.77 Thousand | 396.15 Thousand | -22.95 Thousand | -84.9 Thousand |
| Cash at beginning of period | 4.72 Million | 9.04 Million | 22.13 Million | 2.47 Million | 29.39 Thousand | 40.8 Thousand |
| Cash at end of period | 4.16 Million | 4.72 Million | 9.04 Million | 22.13 Million | 34.68 Thousand | 29.39 Thousand |
| Capital Expenditure | 3.00 | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -561.86 Thousand | -4.31 Million | -13.09 Million | 19.65 Million | 5298.00 | -11.41 Thousand |
| Free Cash Flow | -291.51 Thousand | -4.23 Million | -11.26 Million | -275.19 Thousand | -212.66 Thousand | -275.71 Thousand |
QSI
ENBI
NCRE
2357
688398
UTTAMSUGAR